Tackling Cardiodiabesity: Innovative GLP-1 Strategies to Manage Costs and Improve Outcomes

Available on demand

Amid a growing epidemic of obesity, diabetes, and cardiovascular disease, the surge in demand for GLP-1 specialty drugs like Ozempic and Wegovy is challenging employers to balance patient needs with rising costs. Supply shortages, coupled with off-label use for weight loss, have further complicated coverage decisions. Employers must find ways to offer effective treatments without overwhelming their budgets.

Join our 60-minute panel discussion, where experts will share practical tips on how to manage the rising cost of these medications while supporting employee health.

Learning Objectives:

• Managing Rising GLP-1 Demand — Strategies to balance increasing usage with cost-effective solutions.
• Enhancing Employee Health & Reducing Costs — Practical approaches to improve well-being while controlling healthcare expenses.
• Integrating Lifestyle Programs with Medication — Maximizing health outcomes and cost savings through a combined approach.

Speakers:

• Kasey Raetz, Vice President, Strategic & Clinical Solutions
• Ashley Holzworth-Nash, Vice President,, Strategic & Pharmacy Solutions
• Gerry Stanley, M.D., P-CEO, Chief Medical Doctor
• Melisa Spicer, Senior Director, Clinical Sales & Strategy, Evernorth